Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

Antibody halts triple-negative breast cancer in preclinical models

Triple-negative breast cancer is one of the most aggressive and treatment-resistant cancers. It grows quickly, spreads early, and lacks hormone receptors that make it treatable with targeted therapies. Even when patients initially respond to treatment, the cancer often returns and is more resistant.

January 30, 2026

Vol.52 No.04

By Hayley Kamin

Clinical Roundup

Itismeran autogene + Keytruda demonstrated improvement in recurrence-free survival in neoadjuvant melanoma

Moderna and Merck announced median five-year follow-up data from the phase IIb KEYNOTE-942/mRNA-4157-P201 study, evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualized neoantigen therapy, in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with high-risk melanoma (stage 3/4) following complete resection.

January 30, 2026

Vol.52 No.04

Clinical Roundup

Oral bacterium may promote breast cancer development and spread, Hopkins study finds

Researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy found that an oral bacterium commonly associated with periodontal disease can promote breast cancer initiation, tumor growth, and spread by inducing DNA damage and altering cancer cell behavior.

January 30, 2026

Vol.52 No.04

Drugs & Targets

Trodelvy added to NCCN guidelines as preferred regimen option for first-line metastatic TNBC

Trodelvy (sacituzumab govitecan-hziy) was added to the NCCN Guidelines as a category 1 preferred first-line treatment option for people with metastatic triple-negative breast cancer whose disease is PD-L1 negative (CPS <10) and no germline BRCA1/2 PV.

January 30, 2026

Vol.52 No.04

Clinical Roundup

Trodelvy + Keytruda show potential as new standard of care in first-line PD-L1+ metastatic TNBC, phase III trial finds

Patients saw a 35% reduced risk of disease progression or death for Trodelvy (sacituzumab govitecan-hziy) plus Keytruda (pembrolizumab) (n=221) versus standard of care Keytruda plus chemotherapy (n=222), according to the positive phase III ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy plus Keytruda in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer.

January 23, 2026

Vol.52 No.03

Clinical Roundup

Extracellular vesicles drug delivery mechanism could aid breast cancer treatment, UF study finds

Scientists from the UF Health Cancer Institute have found a way to make treatment for a notoriously aggressive breast cancer more effective.

January 23, 2026

Vol.52 No.03

Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

YOU MAY BE INTERESTED IN

Antibody halts triple-negative breast cancer in preclinical models

Itismeran autogene + Keytruda demonstrated improvement in recurrence-free survival in neoadjuvant melanoma

Oral bacterium may promote breast cancer development and spread, Hopkins study finds

Trodelvy added to NCCN guidelines as preferred regimen option for first-line metastatic TNBC

Trodelvy + Keytruda show potential as new standard of care in first-line PD-L1+ metastatic TNBC, phase III trial finds

Extracellular vesicles drug delivery mechanism could aid breast cancer treatment, UF study finds

Renew today!

Subscriber content

Never miss an issue!

Login